Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics Inc (DE:2UV)
FRANKFURT:2UV
Applied Therapeutics (2UV) Stock Price & Analysis
0 Followers
2UV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.15 - €7.27
Previous Close€4.08
Volume300.00
Average Volume (3M)377.00
Market Cap
€473.38M
Enterprise Value€435.85M
Total Cash (Recent Filing)$49.90M
Total Debt (Recent Filing)$467.00K
Price to Earnings (P/E)N/A
Beta<0.01
Next Earnings
May 09, 2024EPS Estimate
-€0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding105,886,831
10 Day Avg. Volume43
30 Day Avg. Volume377
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-27.42
Price to Sales (P/S)41.66
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue43.62
Enterprise Value/Gross Profit43.62
Enterprise Value/Ebitda-3.72
Forecast
1Y Price Target
€10.71Price Target Upside172.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Applied Therapeutics News
PremiumCompany Announcements
Applied Therapeutics Welcomes Dale Hooks as New CCO
Bulls Say, Bears Say
Bulls Say
Clinical Data InsightsEncouraging SORD deficiency data with statistically significant results.
Financial Health$100M private placement is expected to extend their cash runway into 2026, contributing to financial stability.
Regulatory MilestoneGalactosemia NDA acceptance with priority review, indicating regulatory momentum.
Bears Say
Clinical Trial FailureA pivotal drug has failed to meet the primary endpoint in a major Phase 3 study, casting doubt on its efficacy and future.
Drug Efficacy ConcernsThe effectiveness of a drug for diabetic cardiomyopathy patients already on GLP-1 treatments is under scrutiny, raising concerns about its market relevance.
Regulatory Approval DelaysThe FDA has extended the review period for the New Drug Application (NDA) for a key drug, potentially delaying its market entry.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.06% Other Institutional Investors
99.94% Public Companies and
Individual Investors
2UV FAQ
What was Applied Therapeutics Inc’s price range in the past 12 months?
Applied Therapeutics Inc lowest stock price was €1.15 and its highest was €7.27 in the past 12 months.
What is Applied Therapeutics Inc’s market cap?
Currently, no data Available
When is Applied Therapeutics Inc’s upcoming earnings report date?
Applied Therapeutics Inc’s upcoming earnings report date is May 09, 2024 which is in 5 days.
How were Applied Therapeutics Inc’s earnings last quarter?
Applied Therapeutics Inc released its earnings results on Mar 06, 2024. The company reported -€0.373 earnings per share for the quarter, missing the consensus estimate of -€0.175 by -€0.199.
Is Applied Therapeutics Inc overvalued?
According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued.
Does Applied Therapeutics Inc pay dividends?
Applied Therapeutics Inc does not currently pay dividends.
What is Applied Therapeutics Inc’s EPS estimate?
Applied Therapeutics Inc’s EPS estimate is -€0.15.
How many shares outstanding does Applied Therapeutics Inc have?
Currently, no data Available
What happened to Applied Therapeutics Inc’s price movement after its last earnings report?
Applied Therapeutics Inc reported an EPS of -€0.373 in its last earnings report, missing expectations of -€0.175. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of Applied Therapeutics Inc?
Among the largest hedge funds holding Applied Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Applied Therapeutics Inc’s shares valued at 14M.
---
Applied Therapeutics Stock Smart Score
Company Description
Applied Therapeutics Inc
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
---
2UV Stock 12 Months Forecast
Average Price Target
€10.71
▲(172.39% Upside)
Technical Analysis
Applied Therapeutics
―
Benitec Biopharma
―
Aslan Pharmaceuticals
―
Rocket Pharmaceuticals
―
Crispr Therapeutics AG
―
Best Analysts Covering 2UV
1 Year
1 Year Success Rate
13/27 ratings generated profit
1 Year Average Return
+87.63%
reiterated a buy rating 2 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 48.15% of your transactions generating a profit, with an average return of +87.63% per trade.
---